ANIP Stock — ANI Pharmaceuticals Inc.: Cash, EV, Pipeline

What they do

The Company's mission is “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing therapeutics through its Rare Disease, Generics, and Brands businesses. On September 16, 2024, the Company acquired Alimera Sciences, Inc. ("Alimera").

Source: 10-K FY2025 via SEC EDGAR

Share price

$67.41

Market cap

$1,547.7M

Cash

$420.8M

Enterprise value

$1,424.6M

Balance sheet

Cash	$420.8M
Debt	$297.7M
Net cash	$123.1M
Enterprise value	$1,424.6M
Basic shares	23.0M shares
Fully diluted shares	29.9M shares
Fully diluted market cap	$2,012.9M
Cash per share	$18.33
Quarterly burn	+$56.7M generated

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

23.0M

Pre-funded warrants

0.0M

Options

0.3M

RSUs

1.8M

Warrants

0.0M

Converts

4.3M

Conv preferred

0.0M

ESPP reserve

0.5M

FDSO

29.9M

Cap table as of 2026-06-30.

Price history

Loading ANIP daily closes…

Loading price history…

Next catalyst

ILUVIEN · Est. Nov 15, 2026 · quarter midpoint · guided Now

Recently reported

ILUVIEN Positive · 2026-07-13

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	ILUVIEN SYNCHRONICITY Phase 4 in NIU-PS	Not disclosed	NIU-PS	Q4 2026

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Purified Cortrophin Gel (Repository Corticotropin Injection USP)

Approved · Active

Target ACTH

Indications

Acute gouty arthritis flares (Approved)

Status note Approved commercial product; FDA approved a prefilled syringe format on May 28, 2025. Commercial launch announced January 24, 2022.

ILUVIEN (fluocinolone acetonide intravitreal implant)

Approved · Active Modality: intravitreal implant

Partnerships Licensed from EyePoint (via Alimera collaboration agreement; $75M upfront); Alimera patent rights limited to diseases of the human eye in Europe/Middle East/Africa and certain other territories

Indications

Diabetic macular edema (DME) (Approved)
Chronic non-infectious uveitis affecting the posterior segment (NIU-PS) (Approved)

Status note Approved product; FDA approved an expanded label to include chronic NIU-PS in addition to DME.

Novel pitolisant formulation

Stage not disclosed · Active

Partnerships Co-exclusive license with Harmony/Novitium to develop the formulation; company earns low-single digit royalties on net sales of pitolisant-based products

Indications

Broad central nervous system indications (outside sleep/wake) (Stage not disclosed)

Status note Early-stage development intent only; filing states no clinical stage. Company is primarily a commercial generics/branded pharma; the 10-Q carries no clinical-stage pipeline beyond this candidate.

Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Tang Capital Partners	707,500	no change	2.66%	2026-08-14
Ikarian Capital	272,085	+125,000	3.69%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ANIP — ANI Pharmaceuticals Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Specialist fund holders

Latest news

ANIP — ANI Pharmaceuticals Inc.